TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25877234

Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Number of subjects: 29

Group type: COMPARATOR
Intervention: Bur preparation
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both methods (Er:YAG laser and Bur preparation)
Number of subjects: 29
Study: 24216598

Group type: EXPERIMENTAL
Intervention: Foot massage (10-min duration, every weekday for 3 weeks)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Quiet presence (control group, every weekday for 3 weeks)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Foot massage
Number of subjects: 55

Group type: COMPARATOR
Intervention: Quiet presence (control group)
Number of subjects: 55
Study: 22694878

Group type: EXPERIMENTAL
Intervention: Interactive website intervention
Number of subjects: 603

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 603
Study: 20126343

Group type: COMPARATOR
Intervention: Epidural anesthesia (EA) group (n=40)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Lumbar plexus-sciatic nerve blocks (LPSB) group (n=40)
Number of subjects: 80
Study: 18509873

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (nonanxious controls)
Number of subjects: 0
Study: 15684902

Group type: EXPERIMENTAL
Intervention: Blood sampling through 3‐Fr PICC devices
Number of subjects: 204

Group type: COMPARATOR
Intervention: No blood sampling through 3‐Fr PICC devices (Control)
Number of subjects: 204
Study: 12853831

Group type: EXPERIMENTAL
Intervention: Lubricant with lidocaine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (lubricant without lidocaine)
Number of subjects: 20
Study: 11194981

Group type: EXPERIMENTAL
Intervention: Tramadol for non‐oncologic chronic pain
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Tramadol for postoperative acute pain
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Tramadol for oncologic chronic pain
Number of subjects: 52
Study: 8618434

Group type: EXPERIMENTAL
Intervention: Fludarabine- and high-dose cytarabine-containing regimens
Number of subjects: 144
Study: 1464897

Group type: EXPERIMENTAL
Intervention: Saiko-ka-ryukotsuboreito (S)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dai‐saiko‐to (D)
Number of subjects: 30
Study: 6434367

Group type: EXPERIMENTAL
Intervention: 1 g of LactAid added to milk
Number of subjects: 50

Group type: COMPARATOR
Intervention: Prehydrolyzed milk
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intact milk
Number of subjects: 50
Study: 29902286

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 8010

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 8010

Group type: COMPARATOR
Intervention: Sequential strategy (letrozole followed by tamoxifen)
Number of subjects: 8010
Study: 28296055

Group type: EXPERIMENTAL
Intervention: saxagliptin
Number of subjects: 488

Group type: COMPARATOR
Intervention: acarbose
Number of subjects: 488
Study: 26654625

Group type: EXPERIMENTAL
Intervention: Star Wars music (SWM)
Number of subjects: 103

Group type: COMPARATOR
Intervention: endoscopist-selected popular music (PM)
Number of subjects: 103
Study: 23442547

Group type: EXPERIMENTAL
Intervention: Conventional treatment (compensating extraction of the upper first permanent molar)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Removal of lower first permanent molars but no extraction of the upper
Number of subjects: 400
Study: 21042881

Group type: EXPERIMENTAL
Intervention: 20% mannitol (1.0 g/kg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: 23.4% saline (0.686 mL/kg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 20% mannitol
Number of subjects: 9

Group type: COMPARATOR
Intervention: 23.4% saline
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 20% mannitol and 23.4% saline
Number of subjects: 9
Study: 18704963

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) and platelet-poor plasma (PPP) applied during wound closure
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) and platelet-poor plasma (PPP)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Saline applied in controls
Number of subjects: 52
Study: 16608860

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy during ICU stay
Number of subjects: 970

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy during ICU stay (with at least 3 days of insulin therapy)
Number of subjects: 970

Group type: COMPARATOR
Intervention: Conventional insulin therapy
Number of subjects: 970

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 970
Study: 12941725

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII) therapy
Number of subjects: 132

Group type: COMPARATOR
Intervention: Multiple daily injection (MDI) therapy
Number of subjects: 132
Study: 10903605

Group type: EXPERIMENTAL
Intervention: CIP+MET
Number of subjects: 459

Group type: COMPARATOR
Intervention: PIP/TAZO
Number of subjects: 459
Study: 8840756

Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 50
Study: 1290431

Group type: EXPERIMENTAL
Intervention: 10 mg oral nifedipine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 10 mg intravenous hydralazine
Number of subjects: 24
Study: 6746322

Group type: EXPERIMENTAL
Intervention: Oral vitamin A (10,000 micrograms/d) for 4 weeks
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (21 sex-matched healthy subjects)
Number of subjects: 37
Study: 30999324

Group type: EXPERIMENTAL
Intervention: Junfeng BFS Water (JBW)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (untreated water)
Number of subjects: 60
Study: 29135709

Group type: COMPARATOR
Intervention: Subconjunctival lidocaine and proparacaine drops as needed during surgery
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 2% lidocaine gel
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 5% lidocaine gel
Number of subjects: 45
Study: 25239666

Group type: EXPERIMENTAL
Intervention: ddTMZ + isotretinoin doublet
Number of subjects: 155

Group type: COMPARATOR
Intervention: ddTMZ alone
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Triplet regimens
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Doublet regimens
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Overall survival (OS)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Isotretinoin-containing regimens
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Celecoxib or thalidomide combinations
Number of subjects: 155
Study: 24429164

Group type: EXPERIMENTAL
Intervention: TCZ 8 mg/kg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: TCZ 4 mg/kg
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 22622672

Group type: EXPERIMENTAL
Intervention: Deferiprone–deferoxamine (DFP‐DFO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Deferiprone (DFP) alone
Number of subjects: 0
Study: 19571802

Group type: EXPERIMENTAL
Intervention: Atorvastatin (34 ± 26 mg/day)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Morning dosing of atorvastatin
Number of subjects: 143
Study: 17519550

Group type: EXPERIMENTAL
Intervention: Neuroendoscopy
Number of subjects: 42

Group type: COMPARATOR
Intervention: External ventricular drainage
Number of subjects: 42
Study: 15555502

Group type: EXPERIMENTAL
Intervention: Luteal phase
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Menses phase
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Follicular phase
Number of subjects: 18
Study: 11425971

Group type: EXPERIMENTAL
Intervention: Visualized SLNs
Number of subjects: 136

Group type: COMPARATOR
Intervention: Nonvisualized SLNs
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Older patients with nonvisualized SLNs
Number of subjects: 136
Study: 9875920

Group type: EXPERIMENTAL
Intervention: Continuous display of trend data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternating 24‐hr display of trend data, starting with display in first 24 hrs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternating 24‐hr display of trend data, starting with no display in first 24 hrs
Number of subjects: 0

Group type: COMPARATOR
Intervention: No display of trend data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Staff questionnaires
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parent questionnaires
Number of subjects: 0
Study: 9133199

Group type: EXPERIMENTAL
Intervention: Indomethacin suppository 100 mg
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Ketorolac IM injection 30 mg
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo (two placebos)
Number of subjects: 137
Study: 2251987

Group type: EXPERIMENTAL
Intervention: Urokinase 2 million units as an intravenous bolus before hospital admission (group A)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Urokinase 2 million units as an intravenous bolus after hospital admission (group B)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Urokinase (group A)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Urokinase (group B)
Number of subjects: 78
Study: 543890

Group type: EXPERIMENTAL
Intervention: Nicergoline (10‐methoxy‐1,6‐dimethyl‐ergoline‐8 beta‐methanol‐(5‐bromonicotinate))
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dihydroergotoxin-mesylate (DHETM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31542748

Group type: EXPERIMENTAL
Intervention: Telerehabilitation operated by a low vision therapist
Number of subjects: 60

Group type: COMPARATOR
Intervention: Current self-training standard provided by the device vendor
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Number of subjects: 60
Study: 26715771

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training at 40% of maximal inspiratory pressure (P(Imax)) for 6 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham therapy (5% of P(Imax)) for 6 weeks
Number of subjects: 30
Study: 23545807

Group type: EXPERIMENTAL
Intervention: Daikenchuto (DKT) 2.5 g
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Daikenchuto (DKT) 5 g
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Daikenchuto (DKT) 10 g
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Daikenchuto (DKT)
Number of subjects: 55
Study: 21753726

Group type: EXPERIMENTAL
Intervention: Intranasal application of xenon
Number of subjects: 40
Study: 19082641

Group type: EXPERIMENTAL
Intervention: SabreSource system
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fluoroscopy guidance alone
Number of subjects: 60
Study: 16644856

Group type: EXPERIMENTAL
Intervention: MVD present
Number of subjects: 395

Group type: COMPARATOR
Intervention: Non-MVD
Number of subjects: 395
Study: 15257968

Group type: EXPERIMENTAL
Intervention: Weighted vests
Number of subjects: 514
Study: 11565972

Group type: EXPERIMENTAL
Intervention: Standing tasks at 3 m and 9 m high balconies on firm or deformable surfaces with close visual references included
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standing tasks at ground level
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Deformable surfaces without close visual references
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Close visual references included
Number of subjects: 24
Study: 9316325

Group type: COMPARATOR
Intervention: Conventional postoperative analgesia of intravenous (i.v.) meperidine HCl (Demerol)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Preemptive analgesia using epidural infusion of local anesthetics plus ketamine and morphine during surgery, and intermittent epidural morphine infusion for postoperative pain control when necessary, along with i.v. Demerol as in Group A
Number of subjects: 40

Group type: COMPARATOR
Intervention: Group A
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Group B
Number of subjects: 40
Study: 8466013

Group type: EXPERIMENTAL
Intervention: Propofol infusion
Number of subjects: 78

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 78
Study: 3567016

Group type: EXPERIMENTAL
Intervention: Promethazine 20 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Promethazine 40 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31571349

Group type: EXPERIMENTAL
Intervention: Combined IVIg (2g/kg loading dose, 1g/kg maintenance every 3 weeks) and IVMP (1g every 3 weeks for 18 weeks); cumulative steroid dose 7g
Number of subjects: 20
Study: 30514858

Group type: EXPERIMENTAL
Intervention: Atrophic gastritis (PGI < 30 μg/L or PGI: PGII < 3.0)
Number of subjects: 1591

Group type: EXPERIMENTAL
Intervention: CagA antibody positive
Number of subjects: 1591

Group type: EXPERIMENTAL
Intervention: Atrophic gastritis
Number of subjects: 1591
Study: 26505825

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (Med diet)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low-fat, high-complex carbohydrate diet (LFHCC diet)
Number of subjects: 20
Study: 25248446

Group type: EXPERIMENTAL
Intervention: Active pulmonary rehabilitation training (air-stacking exercise by ambu-bagging and functional electrical stimulation on phrenic nerve and abdominal muscle)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no active pulmonary rehabilitation)
Number of subjects: 22
Study: 22681259

Group type: EXPERIMENTAL
Intervention: Capsaicin 0.1% hydrogel patch
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control hydrogel patch without capsaicin
Number of subjects: 61
Study: 20493191

Group type: EXPERIMENTAL
Intervention: Higher fat (HF) cream cheese
Number of subjects: 10

Group type: COMPARATOR
Intervention: Lower fat (LF) cream cheese
Number of subjects: 10
Study: 17568412

Group type: EXPERIMENTAL
Intervention: 300 mg/kg i.v. glucose
Number of subjects: 24

Group type: COMPARATOR
Intervention: i.v. placebo
Number of subjects: 24
Study: 15743346

Group type: EXPERIMENTAL
Intervention: On medications for heartburn
Number of subjects: 158

Group type: COMPARATOR
Intervention: Off medications for 1 week while symptomatic
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: On and off antireflux medications
Number of subjects: 158

Group type: COMPARATOR
Intervention: Off medications for patients with comorbid conditions
Number of subjects: 158
Study: 12036207

Group type: EXPERIMENTAL
Intervention: Thermal water from Cserkeszölö (active treatment)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Tap water (placebo treatment)
Number of subjects: 58
Study: 9951980

Group type: EXPERIMENTAL
Intervention: High titer measles vaccine
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: High titer measles vaccine with rash
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: High titer measles vaccine without rash
Number of subjects: 224

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study: 1824203

Group type: EXPERIMENTAL
Intervention: Lovastatin (L)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Probucol (P)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 31
Study: 7017966

Group type: EXPERIMENTAL
Intervention: Atenolol 200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 0
Study: 30485658

Group type: EXPERIMENTAL
Intervention: Orobanche rapum extract
Number of subjects: 0
Study: 29081160

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (10 mg/kg loading dose and 10 mg·kg(‐1)·h(‐1) infusion dose)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 211
Study: 25143294

Group type: COMPARATOR
Intervention: VLNC + PLA (very low nicotine content cigarettes with placebo patches)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: VLNC + NIC (very low nicotine content cigarettes with nicotine patches totaling 42mg)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Usual-brand cigarettes
Number of subjects: 57
Study: 23557872

Group type: EXPERIMENTAL
Intervention: Stimulation at CV12 (abdomen)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stimulation at BL32 (sacral)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stimulation at PC6 (forearm), BL20 (back), ST36 (lower leg)
Number of subjects: 0
Study: 21324825

Group type: EXPERIMENTAL
Intervention: Insulin glulisine 3 times daily
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Insulin glulisine 2 times daily
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Insulin glulisine 1 time daily
Number of subjects: 343

Group type: COMPARATOR
Intervention: Insulin glulisine 1 or 2 times daily
Number of subjects: 343
Study: 19147693

Group type: COMPARATOR
Intervention: Placebo (initial 12 weeks) followed by open active treatment as clinically indicated
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Active treatments (fluoxetine, CBT, combination treatment)
Number of subjects: 439
Study: 17723125

Group type: EXPERIMENTAL
Intervention: Fondaparinux 2.5 mg
Number of subjects: 1309

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1309
Study: 14998381

Group type: EXPERIMENTAL
Intervention: Eformoterol Turbohaler 9 microg b.i.d
Number of subjects: 156

Group type: COMPARATOR
Intervention: Salmeterol Accuhaler 50 microg b.i.d
Number of subjects: 156
Study: 11916358

Group type: EXPERIMENTAL
Intervention: Diltiazem treatment
Number of subjects: 72

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 72
Study: 9496329

Group type: EXPERIMENTAL
Intervention: 150 IU of s.c. recombinant human LH
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 150 IU of s.c. recombinant human FSH
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination of recombinant human LH and FSH
Number of subjects: 12
Study: 8110566

Group type: COMPARATOR
Intervention: Group B10 (10 micrograms kg‐1 bolus dose)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Group B20 (20 micrograms kg‐1 bolus dose)
Number of subjects: 40
Study: 3349887

Group type: EXPERIMENTAL
Intervention: Calcium carbonate (6 g daily)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide (7.2 g daily)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control
Number of subjects: 8
Study: 29985228

Group type: EXPERIMENTAL
Intervention: Pilates method training (60 minutes, 3 times per week for 12 weeks)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Pilates method training
Number of subjects: 22
Study: 31647614

Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance (IGT) with albuminuria
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance (IGT) without albuminuria
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus with albuminuria
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance (IGT) without albuminuria developing albuminuria
Number of subjects: 535
Study: 28993394

Group type: EXPERIMENTAL
Intervention: Shape‐Up following cancer treatment programme (12 hours over 8 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 60
Study: 25256304

Group type: EXPERIMENTAL
Intervention: General practitioners' use of argumentation to support treatment advice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study: 22809774

Group type: EXPERIMENTAL
Intervention: Liposomal 4% lidocaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 0
Study: 19898884

Group type: EXPERIMENTAL
Intervention: Exercise training (breathing and aerobic exercises) for 1.5 h, 3 days weekly for 12 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20
Study: 18924387

Group type: EXPERIMENTAL
Intervention: Evidence-based psychosocial interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Traditional and technology-enhanced interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complementary and alternative therapies
Number of subjects: 0
Study: 16611272

Group type: EXPERIMENTAL
Intervention: rifaximin 800 mg b.d.
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: rifaximin 800 mg o.d. + placebo
Number of subjects: 83

Group type: COMPARATOR
Intervention: placebo b.d.
Number of subjects: 83
Study: 14708688

Group type: EXPERIMENTAL
Intervention: 100 mg daily lamivudine therapy
Number of subjects: 0
Study: 11056097

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (0.625 mg) combined with medroxyprogesterone acetate (2.5 mg) daily
Number of subjects: 2763

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2763
Study: 9014880

Group type: EXPERIMENTAL
Intervention: Fact sheets and subsequent discussion
Number of subjects: 33

Group type: COMPARATOR
Intervention: Fact sheets alone
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Fact sheets
Number of subjects: 33
Study: 1507822

Group type: EXPERIMENTAL
Intervention: Plasmapheresis (PA) as a treatment
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Plasmapheresis with elimination of one volume of circulating plasma (VCP)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Plasmapheresis with elimination of 1/2 VCP
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Plasmapheresis with elimination of 1/4 VCP
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 92
Study: 6742082

Group type: EXPERIMENTAL
Intervention: Timolol maleate 0.5% eyedrops (used twice a day)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Indomethacin 25 mg (three times a day, given orally)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Timolol maleate 0.5% eyedrops with Indomethacin
Number of subjects: 9
Study: 31135106

Group type: EXPERIMENTAL
Intervention: Incised groups (skin incised wound model)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (uninjured skin tissue)
Number of subjects: 45
Study: 27935183

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study: 25677354

Group type: EXPERIMENTAL
Intervention: Citalopram plus methylphenidate
Number of subjects: 143

Group type: COMPARATOR
Intervention: Citalopram plus placebo
Number of subjects: 143

Group type: COMPARATOR
Intervention: Methylphenidate plus placebo
Number of subjects: 143
Study: 24307559

Group type: EXPERIMENTAL
Intervention: Predictable saccade task (PRED)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Position predictable saccade task (pPRED)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Time predictable saccade task (tPRED)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Prosaccade task (SAC)
Number of subjects: 45
Study: 22930049

Group type: EXPERIMENTAL
Intervention: Health education intervention
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (no health education intervention)
Number of subjects: 87